PRESS RELEASE ANNOUNCEMENT

First Page		Document Content
Date: 2012-05-01 15:28:24 HIV/AIDS ViiV Healthcare Fixed dose combination GlaxoSmithKline Pfizer Zidovudine Lamivudine Intel Viiv Abacavir/lamivudine Medicine Health Pharmacology		PRESS RELEASE ANNOUNCEMENT Add to Reading List Source URL: www.gsk.ca Download Document from Source Website File Size: 38,74 KB Share Document on Facebook

	MULTI-‐TARGET PREDICTION Willem Waegeman NGDATA Europe Belgium DocID: 1aQSO - View Document
	ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P DocID: 19FAE - View Document
	Shionogi-ViiV Healthcare Starts Phase III Trial for “572-Trii” Fixed-Dose Combination HIV Therapy London, UK, 3 February 2011 – Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the c DocID: 19oLm - View Document
	Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia DocID: 19hox - View Document
	Microsoft Word - Analysis of ViiV-MPP License.docx DocID: 16NiI - View Document